Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) Inhalation Spray is now available for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients.

The Respimat formulation uses mechanical energy to deliver the drug as a slow-moving mist that is independent of the patient’s inspiratory effort. Tiotropium is a long-acting, antimuscarinic agent that inhibits the M3-receptors at the smooth muscle leading to bronchodilation. The bronchodilation following inhalation of tiotropium is predominantly a site-specific effect.

RELATED: Spiriva Respimat Approved for COPD Maintenance

Spiriva Respimat Inhalation Spray contains a dose counter and delivers 2.5mcg tiotropium per actuation. It is supplied as a carton that includes one Respimat cartridge (4g) and one inhaler with 28- or 60-metered actuations.

Spiriva Handihaler (tiotropium bromide inhalation powder) will continue to be available for patients.

For more information call (800) 542-6257 or visit